«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2016年第1期

页码:

92-096

栏目:

综述

出版日期:

2015-09-15

文章信息/Info

Title:

Research advances in ventricular septal intervention in hypertrophic obstructive cardiomyopathy

作者:

郭兰燕; 邢玉洁; 李 妍

（第四军医大学西京医院心内科，陕西 西安 710032）

Author(s):

GUO Lan-yan;  XING Yu-jie;  LI Yan

(Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)

关键词:

心肌病; 梗阻性; 肥厚型; 左室流出道压力阶差; 室间隔介入; 无水酒精室间隔消融术

Keywords:

hypertrophic obstructive cardiomyopathy;  left ventricular outflow tract gradient;  ventricular septal intervention;  anhydrous alcohol septum ablation

分类号:

R654.2

DOI:

-

文献标识码:

A

摘要:

肥厚型心肌病（HCM）是一种并非完全因心脏负荷异常引起的心室壁增厚疾病。尽管HCM是一种常见的心血管疾病，但却缺乏大规模的随机对照临床研究［1］。大约70%的HCM患者存在左室流出道梗阻（LVOTO），LVOTO是决定临床症状，如气短、胸痛、心悸和晕厥的一个重要因素；另外，无论是采取药物治疗还是室间隔切除术或室间隔介入治疗，LVOTO都是长期以来治疗的靶点之一。现将室间隔介入治疗肥厚型梗阻性心肌病（HOCM）的研究进展综述如下。

Abstract:

Hypertrophic cardiomyopathy (HCM) is defined by the presence of increased left ventricular (LV) wall thickness that is not solely explained by abnormal loading conditions. Although HCM is one type of common cardiovascular diseases, it lacks large-scale randomized controlled clinical studies. Almost 70% of HCM patients present with left ventricular outflow tract obstruction (LVOTO), an important clinical decisive factor for symptoms such as dyspnea, chest pain, palpitation, and syncope. LVOTO is one of the therapy targets for either drug therapy or invasive therapy including ventricular septum resection or ventricular septal intervention such as anhydrous alcohol septum ablation (ASA). This article will review the research advances in ventricular septal intervention in HCM.

参考文献/References

[1]Spoladore R,Maron MS,D'Amato R,et al.Pharmacological treatment options for hypertrophic cardiomyopathy:high time for evidence[J].Eur Heart J,2012,33(14):1724-1733.
[2]Elliott PM,Anastasakis A,Borger MA,et al.2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology(ESC)[J]Eur Heart J,2014,35(39):2733-2779.
[3]Menon SC,Ackerman MJ,Ommen SR,et al.Impact of septal myectomy on left atrial volume and left ventricular diastolic filling patterns:an echocardiographic study of young patients with obstructive hypertrophic cardiomyopathy[J].J Am Soc Echocardiogr,2008,21(6):684-688.
[4]Veselka J,Zemánek D,Tomasov P,et al.Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol(1 ml)is still effective[J]. Heart Vessels,2009,24(1):27-31.
[5]Veselka J,Tomasov P,Zemanek D.Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy:a randomized study with a follow-up up to 11 years[J].Can J Cardiol,2011,27(6):763-767.
[6]Jaber WA,Yang EH,Nishimura RA,et al.Immediate improvement in coronary flow reserve after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy[J].Heart,2009,95(7):564-569.
[7]Soliman OI,Geleijnse ML,Michels M,et al.Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy[J].Am J Cardiol,2008,101(9):1321-1327.
[8]Timmer SA,Knaapen P,Germans T,et al.Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy[J].Am J Physiol Heart Circ Physiol,2011,301(1):129-137.
[9]Veselka J,Tomasov P,Zemanek D.Mid-term outcomes of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in patients with sigmoid versus neutral ventricular septum[J].J Invasive Cardiol,2012,24(12):636-640.
[10]Leonardi RA,Townsend JC,Patel CA,et al.Alcohol septal ablation for obstructive hypertrophic cardiomyopathy:outcomes in young, middle-aged,and elderly patients[J].Catheter Cardiovasc Interv,2013,82(5):838-845.
[11]Noseworthy PA,Rosenberg MA,Fifer MA,et al.Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy[J].Am J Cardiol,2009,104(1):128-132.
[12]Klopotowski M,Chojnowska L,Malek LA,et al.The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy[J].Clin Res Cardiol,2010,99(5):285-292.
[13]Axelsson A,Weibring K,Havndrup O,et al.Atrioventricular conduction after alcohol septal ablation for obstructive hypertrophic cardiomyopathy[J].J Cardiovasc Med(Hagerstown),2014,15(3):214-221.
[14]Veselka J,Lawrenz T,Stellbrink C,et al.Low incidence of procedure-related major adverse cardiac events after alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy[J].Can J Cardiol,2013,29(11):1415-1421.
[15]Veselka J,Lawrenz T,Stellbrink C,et al.Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy:a European multicenter and multinational study[J].Catheter Cardiovasc Interv,2014,84(1):101-107.
[16]Zemanek D,Veselka J,Chmelova R.Infective endocarditis after alcohol septal ablation for obstructive hypertrophic cardiomyopathy[J].Int Heart J,2008,49(3):371-375.
[17]Veselka J,Krejci J,Tomasov P,et al.Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy:a comparison with general population[J].Eur Heart J,2014,35(30):2040-2045.
[18]Jensen MK,Prinz C,Horstkotte D,et al.Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile[J].Heart,2013,99(14):1012-1017.
[19]Sorajja P,Ommen SR,Holmes DRJr,et al.Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy[J].Circulation,2012,126(20):2374-2380.
[20]Knyshov G,Lazoryshynets V,Rudenko K,et al.Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy?[J].Interact Cardiovasc Thorac Surg,2013,16(1):5-9.
[21]Steggerda RC,Damman K,Balt JC,et al.Periprocedural Complications and Long-Term Outcome After Alcohol Septal Ablation Versus Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy:A Single-Center Experience[J].JACC Cardiovasc Interv,2014,7(11):1227-1234.
[22]Alam M,Dokainish H,Lakkis NM.Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs.myectomy: a meta-analysis[J].Eur Heart J,2009,30(9):1080-1087.
[23]Krejci J,Gregor P,Zemanek D,et al.Comparison of long-term effect of dual-chamber pacing and alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy[J].Scientific World Journal,2013,2013:629650.
[24]Durand E,Mousseaux E,Coste P,et al.Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up[J].Eur Heart J,2008,29(3):348-355.
[25]Oto A,Aytemir K,Okutucu S,et al.Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy[J].J Interv Cardiol,2011,24(1):77-84.
[26]Lawrenz T,Borchert B,Leuner C,et al.Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months'follow-up in 19 patients[J].J Am Coll Cardiol,2011,57(5):572-576.

备注/Memo

备注/Memo:

收稿日期：2014-11-19.
通讯作者：李妍，副教授，主要从事冠心病和心肌病诊疗研究 Email：fireman @fmmu.edu.cn
作者简介：郭兰燕，住院医师，硕士 Email：guolany@163.com

常用功能

更新日期/Last Update: 2015-09-16